BioNexus Gene Lab Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.9M
- Price
- $1.34
- % Change (Daily % change from the live per-ticker quote feed.)
- +8.06%
- Volume
- 27.5K
About
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
Quick stats
Shares outstanding2.9M
Computed float1.2M
Float / shares42.2%
Cash runway (months)13.7
Key info
SectorIndustrials
IndustryIndustrial - Distribution
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001737523
AI Summary
AI-generated1/4
standardbullishpartnership
BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence
BioNexus Gene Lab (BGLC) signed a definitive agreement with Ruanyun Edai Technology (RYET) for a 10-year exclusive Malaysian healthcare licence to the CogniAI document-intelligence platform.
BGLC will pay the US$3.5 million licence consideration entirely in stock (410,000 shares) plus 150,000 shares in a share exchange, with a 10% royalty to RYET on receipts collected and no cash outlay.
The first target is Malaysia's RM1 billion public healthcare digitalization programme covering 150 hospitals and 2,000+ clinics, but BGLC has not been awarded any government contract and closing remains subject to due diligence, approvals, and technology delivery by December 4, 2026.
Red flags
- closing is pending and either party may terminate if closing has not occurred by March 31, 2027
- BGLC has not been awarded any government contract; revenue depends entirely on procurement
- licence consideration paid in shares creates dilution (560,000 total shares issued)
- both parties have going-concern uncertainties disclosed in filings
- deal subject to required PRC technology-export approvals
- US$3.5 million consideration is a contractual amount, 'not a statement of fair value'